Dynavax Appoints Kelly MacDonald as Chief Economic Officer

&#13

EMERYVILLE, Calif., Jan. 20, 2021 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company centered on establishing and commercializing vaccines, these days announced that Kelly MacDonald has been appointed Senior Vice President and Chief Monetary Officer. Ms. MacDonald will join the company successful March 1, 2021.

&#13
&#13

Dynavax Appoints Kelly MacDonald as Chief Financial Officer

&#13
&#13

As earlier declared, right after 14 several years at Dynavax, Main Monetary Officer Michael Ostrach is retiring. Mr. Ostrach has agreed to continue to be offered as an advisor to the Enterprise thereafter.

&#13
&#13

“Michael’s contributions and unwavering dedication to Dynavax have been significant to the good results of our organization. We are extremely fortunate to have had his direction above the many years and now as a strategic advisor to assure a seamless transition to his successor,” commented Ryan Spencer, Main Govt Officer of Dynavax. “Kelly is an achieved economical chief with a deep being familiar with of corporate and commercial finance and will be an asset as we grow our small business of producing vaccines to support avert the spread of infectious conditions. On behalf of the board and the other associates of the government workforce, it is a satisfaction to welcome Kelly to Dynavax.”

&#13
&#13

“This is an interesting time to sign up for Dynavax as it carries on to construct a leading vaccine company, addressing urgent international overall health desires,” commented Kelly MacDonald. “I share the lengthy-phrase motivation to Dynavax’ vision of collaboration, innovation and development and appear forward to primary the finance and accounting workforce in executing the firm’s strategic and monetary aims.”

&#13
&#13

Ms. MacDonald joins Dynavax from Ironwood Pharmaceuticals where by she held roles of escalating duty. In her remaining role at Ironwood Ms. MacDonald served as Main Accounting Officer and Vice President, Finance exactly where she led the Firm’s corporate accounting and finance processes, enterprise chance administration, treasury and funds allocation technique. While at Ironwood, she also held different other managerial roles, supplying finance and accounting help for the firm’s strategic organizing, R&D portfolio management, world organization growth, product launches and professional execution. Prior to joining Ironwood, Kelly was a Supervisor in the Well being Industries Assurance Apply at PricewaterhouseCoopers, mostly serving clients in lifetime sciences and engineering sectors.

&#13
&#13

Ms. MacDonald is a Licensed General public Accountant (CPA) and holds a Grasp of Enterprise Administration from the Isenberg School of Administration at the University of Massachusetts and a Bachelor of Science in Accounting from Fairfield University.

&#13
&#13

About Dynavax
&#13
Dynavax is a professional stage biopharmaceutical company developing and commercializing novel vaccines. The Company’s to start with commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is permitted in the U.S. for avoidance of an infection induced by all recognised subtypes of hepatitis B virus in adults age 18 several years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant by means of study collaborations and partnerships. Existing collaborations are concentrated on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For far more facts, take a look at www.dynavax.com and stick to the business on LinkedIn.

&#13
&#13

Contacts:

&#13
&#13

Nicole Arndt, Senior Supervisor, Trader Relations
[email protected] 
&#13
510-665-7264

&#13
&#13

Derek Cole, President
&#13
Investor Relations Advisory Solutions
[email protected]

&#13
&#13

(PRNewsfoto/Dynavax Technologies)

&#13
&#13

Cision Watch primary material to download multimedia:http://www.prnewswire.com/news-releases/dynavax-appoints-kelly-macdonald-as-chief-monetary-officer-301211428.html

&#13
&#13

Supply Dynavax Systems

&#13